NIMG-61. USING MACHINE LEARNING TO BUILD RADIOMICS MODELS THAT DISTINGUISH REGIONS OF GLIOBLASTOMA RECURRENCE VS TUMOR PROGRESSION ON MRI. (11th November 2019)

• Record Type: Journal Article
• Authors: Yoon, Hyunsoo; Hawkins-Daarud, Andrea; Save, Akshay; Singleton, Kyle; Clark-Swanson, Kamala; Wang, Lujia; Bendok, Bernard; Mrugala, Maciej; Wu, Teresa; Bruce, Jeffrey; Hu, Leland; Li, Jing; Canoll, Peter D; Swanson, Kristin
• Is Part Of: Neuro-oncology. Volume 21(2019)Supplement 6
• Page Start: vi175
• Page End: vi175
• Publication Date: 2019-11-11
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noz175.730
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Recurrent glioblastoma is challenging to distinguish from so called "treatment effect" on routine clinical imaging. Further, within tumor heterogeneity reveals that some regions can be histologically dominated by tumor progression whilst others can be dominated by secondary effects of treatment response. Apparent tumor progression on MRI can be very difficult to manage clinically as it is unclear the degree to which the imaging changes are actually tumor progression vs response to treatment (including inflammatory response and necrosis). In this analysis, we study a unique cohort of patients for whom image localized-biopsies reveal heterogeneity in response vs progression. Our dataset included 70 biopsy samples from 32 patients with GBM each histolopatholgically characterized for tumor abundance vs immune infiltrate. Six multiparametric MRI contrasts were available, including T1, T1gd, T2, FLAIR, SWI, and ADC. Images were co-registered. Radiomic (statistical + texture) features were extracted from the region of six image contrasts locally matched with each biopsy sample. Machine learning models were built to predict each biomarker using radiomic features. Leave-one-out cross validation was used to evaluate the prediction accuracy. Radiomic features were found to be informative to the prediction of biomarkers. ANOVA tests show significant improvement of using radiomic features compared with the null model. The prediction accuracy was higher when considering the biomarkers on a binary scale using the median as the cutoff than on a numerical scale. Spatially-informed radiomics models for tumor progression vs treatment effect are possible and can play an instrumental role in navigating confounding imaging changed common during treatment progression.